Streetbeat News

Regulatory

ADIL

Adial Pharmaceuticals has announced that its allowed claims cover the detection of select genotypes for the use of AD04 in treating Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD) patients.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 2:00 pm

ADIL

Adial Pharmaceuticals has been awarded a Notice of Allowance for a key patent that combines the use of the company's proprietary genetic diagnostic with AD04 to treat alcohol and drug dependence.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 1:59 pm

COIN

Coinbase (NASDAQ:COIN) has identified Ireland as its principal center for EU operations and regulatory affairs. The company has forwarded its licensing application to the Central Bank of Ireland in preparation for the upcoming enactment of the European Union’s Markets in Crypto-Assets (MiCA) regulation. The approval of the MiCA license in Ireland would enable Coinbase to extend its services across various EU nations including Germany, France, Italy, and the Netherlands.

Portfolio Pulse from Murtuza Merchant

October 19, 2023 | 1:16 pm

CTRM

Castor Maritime Inc. has received a 180-day extension from Nasdaq to meet the minimum bid price requirement. This extension will allow the company more time to increase its stock price and remain listed on the Nasdaq exchange.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 1:10 pm

MYMD

MyMD Pharmaceuticals announced preclinical study results showing that its novel cannabidiol analog, Supera-CBD, reduced acute inflammatory pain. The drug provided long-lasting pain relief lasting up to five hours. The company was also issued Japanese Patent No. 7293561 B2, covering Supera-CBD as a new molecular entity, in pharmaceutical formulations, and for use in therapeutic treatments.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 1:07 pm

NVO

The European Medicines Agency and the UK's Medicines and Healthcare Products Regulatory Agency have warned about fake pre-filled pens of Novo Nordisk's diabetes drug Ozempic being found at wholesalers in the EU and UK. There is no evidence that any of these falsified pens have been dispensed to patients. Novo Nordisk recently raised its FY23 guidance due to surging sales of its obesity and weight-loss drugs.

Portfolio Pulse from Vandana Singh

October 19, 2023 | 12:57 pm

GRI

GRI Bio has presented translational data demonstrating a connection between NKT cells and the pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference. The company is on track to launch a Phase 2a biomarker study for its lead program, GRI-0621, a type 1 invariant NKT (iNKT) antagonist for the treatment of IPF, before the end of the year.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 12:50 pm

GILD

PFE

Pfizer Inc is planning to increase the price of its Covid-19 drug Paxlovid to $1,390 for a five-day course, more than double the initial price paid by the U.S. government. This decision has been criticized by doctors and patient advocates due to concerns about patient access. Pfizer defended the price increase, stating it reflects the value Paxlovid provides in reducing Covid-19-related hospitalizations and deaths. The company also plans to offer discounts to uninsured patients or those covered by Medicaid.

Portfolio Pulse from Vandana Singh

October 19, 2023 | 12:45 pm

SXTP

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) will present a scientific poster on the long-term safety data of tafenoquine for malaria prevention at the ILADS 2023 annual scientific meeting. The company will also review the use of 8-aminoquinolines in treating malaria and babesiosis. Tafenoquine is approved for malaria prophylaxis in the US under the product name ARAKODA®. However, it has not been proven effective for treatment or prevention of babesiosis and is not FDA approved for such indications.

Portfolio Pulse from Happy Mohamed

October 19, 2023 | 12:42 pm

GBTC

Grayscale Investments, the world's largest crypto asset manager, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) to register shares of Grayscale Bitcoin Trust (GBTC) under the Securities Act of 1933. GBTC plans to list the shares on NYSE Arca under the symbol GBTC, and issue the shares on an ongoing basis upon approval of NYSE Arca's application.

Portfolio Pulse from Happy Mohamed

October 19, 2023 | 12:39 pm